NanoViricides, Inc. (NYSE American: NNVC) announced it has submitted an application to the Democratic Republic of Congo’s regulatory agency for approval to initiate a Phase II clinical trial of its NV-387 Oral Gummies as a treatment for the current Bundibugyo ebolavirus outbreak. The company has retained Om Sai Clinical Research Private Limited as the contract research organization for the study, with drug supplies already positioned in the DRC. NV-387 is an orally administered broad-spectrum antiviral that targets host-side mechanisms viruses rely on to infect cells, a strategy the company believes may reduce the likelihood of viral resistance.
The planned study builds on NanoViricides’ ongoing Phase II Mpox trial in the DRC and comes as the company seeks to address an outbreak that, according to the release, has resulted in more than 930 deaths and nearly 2,400 confirmed cases since May. The company stated that NV-387’s oral formulation could offer logistical advantages over infusion-based therapies in resource-limited settings and, if successful, could support development of a broad-spectrum treatment for Ebola and other filoviruses. More details are available in the full press release at https://ibn.fm/tmrCX.
NanoViricides is a clinical-stage company focused on creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is being developed for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as Mpox, smallpox, and measles. The company’s platform technology and programs are based on TheraCour nanomedicine technology, licensed from TheraCour Pharma, Inc. For further updates on NanoViricides, visit the company’s newsroom at https://ibn.fm/NNVC.
